'Modern Family' star Eric Stonestreet reveals he's been taking Mounjaro for type 2 diabetes since 2022. It has changed his life in 2 ways.
Eric Stonestreet told Business Insider that he has type 2 diabetes and uses Mounjaro to treat it.
Stonestreet kept his diagnosis a secret for years because he was ashamed, but decided to speak out.
Mounjaro helped him control his diabetes and motivated him to develop healthier habits, he said.
In 2009, Eric Stonestreet took on the role that would change his life: the fun and flamboyant stay-at-home dad Cam on "Modern Family." But Stonestreet's life changed in more ways than one that year: he was also diagnosed with type 2 diabetes.
The Emmy-winning actor told Business Insider that he started taking Mounjaro — a GLP-1 agonist drug similar to Ozempic — in 2022 to treat his diabetes. He is speaking publicly for the first time about having the condition and using Mounjaro, in partnership with its manufacturer, Eli Lilly.
The active ingredient in GLP-1s mimics a hormone of the same name, which the gut produces naturally to help balance blood sugar.
After researchers realized GLP-1s were causing patients to lose significant amounts of weight, largely through appetite suppression, medications such as Wegovy (known as Ozempic for diabetes) and Zepbound (the Mounjaro equivalent) were approved for weight loss in 2023 and have soared in popularity in the years since.
Stonestreet, 53, said the medication changed his life by helping him keep his diabetes under control and motivating him to adopt a healthier lifestyle. He said he wants to raise awareness of type 2 diabetes.
"We have to get people talking about it and take away the stigma," Stonestreet said.
Stonestreet said his type 2 diabetes diagnosis was wrapped up in shame about being a bigger person.
He grew up on a farm in Kansas and played lots of sports. He looks back on himself as a slim kid, but didn't always think that way.
"I've never thought of myself as anything other than a fat or overweight kid," Stonestreet said. "In seventh grade, I was almost six foot, 175 pounds. I was the biggest kid in class. But when I see pictures of myself back then, I'd do anything to have that physique now. So I think in a way, how I viewed myself and how I look sort of manifested itself."
Stonestreet started putting on weight in his senior year, and stayed a similar size for about 20 years. "It's only in the last 15 years that I felt like I started to put on too much weight," he said.
After he was diagnosed with type 2 diabetes, Stonestreet was in denial. He "took some simple treatments that the doctor recommended," but didn't tell anyone about it.
"I was embarrassed by it, ashamed, just because here I am, this heavy set guy, of course I have type two diabetes, and everybody would just be like, 'Well, duh,'" he said.
But type 2 diabetes doesn't only affect people with larger bodies. It's caused by insulin resistance, and while research suggests that 80 to 85% of the risk is tied to obesity, other factors — including genetics, activity levels, race, and age — also play a role.
"You never know what someone living with type 2 diabetes looks like," Stonestreet said. "It's easy to paint with a broad brush in that way."
Stonestreet decided to open up to his parents about having the disease when his dad was diagnosed with leukaemia. He later died in 2021.
"Seeing my dad's health fail and my mom have other health issues unrelated to type 2, that got them really talking about their diabetes. And then that got me to admit to them that I had it," he said.
This Easter, he found out two of his cousins have type 2 diabetes, too. "Never knew that in my life," he said.
Stonestreet said he and his cousins feeling comfortable to open up about having type 2 diabetes is what he hopes his campaign will achieve on a wider scale.
Stonestreet had tried other treatments for diabetes, but nothing had as profound an effect as Mounjaro, he said.
"My doctor at the time was very excited about it coming out; he told me, 'Eric, when this drug hits the market, you're going to be one of the first people on it. It's going to be great for you.' And it has been," he said. The Food and Drug Administration approved the drug for diabetes in 2022.
Mounjaro is injected weekly, and Stonestreet built up to the highest dose. It has helped him lower his A1C (average blood sugar levels) to pre-diabetic numbers, he said.
The medication's efficacy inspired him to work on his overall lifestyle, and he started moving for 150 minutes a week, mostly by walking. Patients on Mounjaro and other GLP-1s are advised to eat a nutritious diet and exercise regularly.
"It's been crazy. The numbers don't lie, and it's just been slowly ticking down," Stonestreet said, referring to his A1C. "Once I really started focusing on diet and exercise to go along with Mounjaro, my A1C just fell off a cliff. It's remarkable."
He added: "All of a sudden, I felt like I needed to be accountable to it, because it's showing up every day to do something for me."
By changing his outlook on his lifestyle, the medication has been a "life-changer," he said.
"Those doctors at Lilly, scientists, researchers, they did all the work to create it. And so I'm not going to just spit in its face and all their faces by not doing at least my part to make the drug as effective as it can," Stonestreet said.
In studies, patients have lost up to 20% of their bodyweight on Mounjaro, but that was never Stonestreet's focus, and he lost a few pounds when he started on it.
He also said he didn't experience common side effects of the drug, such as nausea and constipation. GLP-1 drugs are considered a long-term treatment, and some patients have found the side effects too challenging to continue.
Stonestreet uses a continuous glucose monitor to track his blood sugar levels and treats it like a game.
"I'm logging information constantly, and it's turned into something I'm addicted to," he said. "Making sure my blood sugar is always where it needs to be."
He watches what he eats but allows himself to "mess up every once in a while."
Ultimately, Stonestreet thinks it's important to have realistic expectations in life.
"If I had moved to Los Angeles to be a lifeguard on 'Baywatch', I would've had a very unfulfilled career," he said. "Could I have been a sunburn victim on 'Baywatch'? Sure. On the beach, visiting from Kansas? Completely realistic."
He added: "So I think if I can give people advice — and it's not always easy to take advice from somebody that's doing it — but it's just set yourself realistic expectations. Don't say, 'Man, I'm going to run a marathon', or 'I'm never going to have a piece of candy again in my life'. Just bit by bit, piece by piece."
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Eli Lilly telehealth deals to prevent sale of compounded GLP-1s
Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites. Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals. Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Eli Lilly revealing a caveat to its agreement with telehealth firms including its recent deals with Ro and LifeMD. Yahoo! Finance's Anjalee Khemlani joining us now with more. So tell us more about this caveat, Anj. Bloomberg reported some details about Eli Lilly's agreements with these telehealth companies, and that includes, as you mentioned, some of the ones that are not the big names we know. So not Hims & Hers, and that is sort of the point of this mention, that Lilly has created a route to be able to get their product in with these companies, while also ensuring that the compounded versions are not being sold on the same site and they're not competing with those compounded versions. Important to note though, and we got a statement from Eli Lilly that they are actually helping their competitor Novo Nordisk out, because in the comment I got, it said quote, 'Anyone continuing to sell mass compounded tirzepatide or semaglutide products including by referring to them as personalized, tailored or something similar is breaking the law.' That's a direct quote from Eli Lilly, and the call out on personalized and tailored is because that is a loophole that certain compounded pharmacies are currently trying to use to keep these compounded GLP-1s on the market, saying that they don't entirely have to shut down despite the FDA bringing those products off the shortage list and therefore stopping compounded products. Now, this is interesting because we have seen a number of telehealth companies, not just partner with Eli Lilly, but also Novo Nordisk and their telehealth platform. And Hims & Hers is currently partnered with Novo Nordisk. So it seems that that caveat was not part of the agreement there. So two different sort of competing strategies to try and compete with compounded products and get them off the market, or not at all in the case of Novo Nordisk. But this is the reason why that Lilly caveat is so interesting. There are some companies that are part of the platform that do continue to sell compounded products, and it remains to be seen how Lilly does manage those and how they go after them. Anj, I'm just going to put a fine point on it, Hims & Hers, I'm looking at the shares are down about 3%, and it looks like it is indeed linked to this. Of course, Hims & Hers is also up, like, 128% this year. That's right, yes, they definitely have been benefiting from the GLP-1 boost, and one of the biggest ones that we can track as a publicly traded company. And that's sort of the benefit that they've had is that no matter what has been happening in GLP plus telehealth world, they have been the benefactors of that in their stock price. And now to this point when the sort of mask is taken off on, on some of these agreements, it comes down to whether or not Hims decides to join the, the entire rest of the community and the other telehealth players in taking down these compounded products or whether or not they continue to sell them. I did speak to previously one of the telehealth companies, and they said that they had given their members a chance to buy sort of a year's worth of supply of compounded products by the deadline, and some clients did take advantage of that. So there clearly is still a market for these products based on their price, and who's trying to, you know, access them, but it seems like the companies are working with the authorities to try and do a better job of policing that and see, and making sure that the branded products are the ones now on the market. Anj, thanks, as always, for your coverage of the GLP-1 space, appreciate it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Eli Lilly telehealth deals to prevent sale of compounded GLP-1s
Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites. Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals. Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Yahoo
3 hours ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool